Biogen Inc.
corporate_fare Company Profile
Biogen Inc. (NASDAQ:BIIB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 48 items for BIIB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for BIIB spans 10-Q, 8-K.
Recent high-impact activity:
- Real-World Data Show 76% Slower Alzheimer's Progression on LEQEMBI
- Diranersen Shows Growing Benefit at Two Years in Early Alzheimer's
- Biogen's DZP Hits Primary Endpoint in Late-Stage Lupus Trial
- Biogen 10-Q: Q3 Revenue Up 11% to $2.80B, GAAP EPS $(0.14) on $283.8M IPR&D Charges
- Biogen Q3 Revenue Up 11% to $2.8B; Low End of FY26 EPS Guidance Raised
Financial Snapshot
Short Interest & Short Volume
3.96 days to coverFINRA reported short interest of 5,453,103 shares in BIIB as of the October 30, 2026 settlement, a 0.9% decrease from the prior period — about 4.0 days to cover at its recent average daily volume. On November 20, 2026, 68.4% of BIIB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.